Management of Intractable Headache in Idiopathic Intracranial Hypertension (IIH)

First-line Approaches

The American Academy of Neurology recommends a stepwise approach starting with migraine-targeted therapies, with topiramate as a preferred option due to its dual benefits of carbonic anhydrase inhibition and weight loss properties 1, 2
Acetazolamide is the first-line pharmacological treatment for IIH with a starting dose of 250-500mg twice daily, titrating up as needed to a maximum of 4g daily, although this information is from Praxis Medical Insights, topiramate should be strongly considered as an alternative or adjunct therapy due to its multiple benefits, including carbonic anhydrase inhibition, weight loss promotion, and migraine prophylaxis effects 1, 3, 4, 5
When using topiramate, start with 25mg and escalate weekly to 50mg twice daily, with appropriate counseling regarding side effects and contraceptive interference 5

Short-term analgesics may be helpful in the first few weeks following diagnosis, including NSAIDs or paracetamol, and indomethacin may be particularly beneficial due to its effect on reducing intracranial pressure 5
For migrainous attacks, triptans may be used in combination with either NSAIDs or paracetamol and an antiemetic with prokinetic properties, but limit triptan use to 2 days per week or a maximum of 10 days per month to prevent medication overuse headache 2, 3

For patients with migrainous features, consider migraine preventatives, and candesartan can be a useful alternative due to its lack of weight gain and depressive side effects 1, 2
Venlafaxine is weight neutral and helpful with depression symptoms, which is a frequent comorbidity in IIH, and botulinum toxin A may be useful in those with coexisting chronic migraine 1, 2, 3

CSF diversion is generally NOT recommended as a treatment for headache alone in IIH, and following CSF diversion, 68% will continue to have headaches at 6 months and 79% by 2 years 1, 6
Neurovascular stenting is not currently recommended as a treatment for headache in IIH, due to limited evidence from non-randomized studies, small sample sizes, and lack of long-term follow-up 1, 4

Implement strategies to limit caffeine intake, ensure regular meals and adequate hydration, establish an exercise program and sleep hygiene, and consider behavioral and stress management techniques such as yoga, cognitive-behavioral therapy, and mindfulness 2, 3

Follow-up intervals should be based on papilloedema grade and visual field status, and patients need clear explanation of how their headaches may change over time and how to minimize the risks of developing medication overuse headache 3, 4

Failing to recognize medication overuse headache, which can prevent optimization of preventative treatments, and using medications that promote weight gain, which can worsen IIH 1, 2, 3
Relying on CSF diversion procedures for headache management alone without addressing the migrainous component of headaches, and not starting preventative medications early enough, as they can take 3-4 months to reach maximal efficacy 2, 3, 6, 7

To confirm idiopathic intracranial hypertension (IIH) and stratify risk, clinicians should document visual acuity, pupil examination, formal visual‑field assessment, dilated fundus examination with papilledema grading, body‑mass‑index calculation, and lumbar‑puncture opening pressure. 8

Severe papilledema – if visual fields are normal or improving, review within 4 weeks; if fields are stable, review within 1 week.
Moderate papilledema – normal fields: review in 3‑4 months; improving or stable fields: review in 1‑3 months; worsening fields: review within 2 weeks.
Mild papilledema – normal fields: review in 6 months; improving fields: review in 3‑6 months; stable fields: review in 3‑4 months; worsening fields: review within 4 weeks.

CSF diversion procedures (e.g., ventriculoperitoneal shunting) are not recommended as a treatment for headache alone in IIH. 9
After shunt placement, 68 % of patients still experience headaches at 6 months and 79 % at 2 years. 9
Shunt revision should be undertaken only when papilledema threatens vision, not for headache alone. 9
Neurovascular (venous) stenting is currently not indicated for headache management in IIH. 9

Patients with headache unresponsive to medical therapy should be referred to a specialist headache service. 9
A multidisciplinary discussion is advised to consider intracranial‑pressure (ICP) monitoring, which helps differentiate pressure‑related headache from a migrainous component. 9
ICP monitoring should be performed before contemplating CSF diversion; diversion is considered only when elevated ICP is confirmed as the primary driver of headache. 9

Acetazolamide: requires a clear risk‑benefit discussion; manufacturers advise against use because of teratogenic effects observed in animal studies. 9
Topiramate: contraindicated in pregnancy due to documented higher rates of fetal abnormalities; it must be stopped immediately if pregnancy occurs. 9
Ongoing multidisciplinary communication among neurology, obstetrics, and ophthalmology teams is essential throughout pregnancy, delivery, and the postpartum period. 8